Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.

Authors

Frederick Locke

Frederick Lundry Locke

H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

Frederick Lundry Locke , Nancy L. Bartlett , Caron A. Jacobson , Olalekan O. Oluwole , Javier Munoz , Lazaros J. Lekakis , Max S. Topp , Irit Avivi , Jenny J. Kim , Rong Chu , Lianqing Zheng , John M. Rossi , Adrian Bot , Sattva Swarup Neelapu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT02348216

Citation

J Clin Oncol 38: 2020 (suppl; abstr 8012)

DOI

10.1200/JCO.2020.38.15_suppl.8012

Abstract #

8012

Poster Bd #

345

Abstract Disclosures

Similar Posters